22 research outputs found

    In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells." J Pharmacol Exp Ther 310(3

    No full text
    ABSTRACT Efalizumab (Raptiva) is a humanized CD11a-specific monoclonal antibody that was recently approved for the treatment of moderate to severe psoriasis. In psoriasis patients, the rate of efalizumab clearance from serum is related to T-cell surface expression of CD11a, suggesting a receptor-mediated clearance model for efalizuma
    corecore